9-104831048-C-G
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM1PM5PP3_Strong
The NM_005502.4(ABCA1):āc.1769G>Cā(p.Trp590Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000514 in 1,613,612 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. W590L) has been classified as Likely pathogenic.
Frequency
Consequence
NM_005502.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ABCA1 | NM_005502.4 | c.1769G>C | p.Trp590Ser | missense_variant | 14/50 | ENST00000374736.8 | NP_005493.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ABCA1 | ENST00000374736.8 | c.1769G>C | p.Trp590Ser | missense_variant | 14/50 | 1 | NM_005502.4 | ENSP00000363868.3 | ||
ABCA1 | ENST00000678995.1 | c.1769G>C | p.Trp590Ser | missense_variant | 14/50 | ENSP00000504612.1 |
Frequencies
GnomAD3 genomes AF: 0.0000264 AC: 4AN: 151748Hom.: 0 Cov.: 29
GnomAD3 exomes AF: 0.0000398 AC: 10AN: 251454Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135900
GnomAD4 exome AF: 0.0000540 AC: 79AN: 1461864Hom.: 0 Cov.: 36 AF XY: 0.0000536 AC XY: 39AN XY: 727232
GnomAD4 genome AF: 0.0000264 AC: 4AN: 151748Hom.: 0 Cov.: 29 AF XY: 0.0000135 AC XY: 1AN XY: 74082
ClinVar
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | May 06, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 19, 2023 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies have shown that this missense change affects ABCA1 function (PMID: 12509412, 16873719, 18776170, 24097981). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ABCA1 protein function. ClinVar contains an entry for this variant (Variation ID: 9490). This variant is also known as G1709C, Trp530Ser. This missense change has been observed in individual(s) with Tangier disease (PMID: 10431237). This variant is present in population databases (rs137854496, gnomAD 0.03%). This sequence change replaces tryptophan, which is neutral and slightly polar, with serine, which is neutral and polar, at codon 590 of the ABCA1 protein (p.Trp590Ser). - |
Tangier disease Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 01, 1999 | - - |
ABCA1-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | The ABCA1 c.1769G>C (p.Trp590Ser) missense variant is also referred to in the literature as p.Trp530Ser. The variant has been identified in a compound heterozygous state in one individual with Tangier disease who exhibited severely reduced HDL-C levels (Bodzioch et al. 1999). Family studies showed that the patient's father, son, and granddaughter were heterozygous for the p.Trp590Ser variant and also exhibited subnormal HDL-C levels. The p.Trp590Ser variant was absent from 200 control chromosomes (Bodzioch et al. 1999) and is reported at a frequency of 0.00060 in the European (Finnish) population of the Exome Aggregation Consortium. Functional studies indicate that the p.Trp590Ser variant significantly decreases cholesterol and phospholipid efflux but does not significantly impair apoA-I binding (Vaughan et al. 2009; Nagao et al. 2009; Kim et al. 2011; Wang et al. 2013). The evidence for this variant is limited. Therefore, the p.Trp590Ser variant is classified as a variant of unknown significance but suspicious for pathogenicity for ABCA1-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at